Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387294016> ?p ?o ?g. }
- W4387294016 abstract "Status epilepticus in poststroke epilepsy is a challenging condition because of multiple vascular comorbidities and the advanced age of patients. Data on third-generation antiseizure medication (ASM) in this condition are limited. The aim of this study was to evaluate the efficacy of third-generation ASMs in the second- or third-line therapy of benzodiazepine-refractory status epilepticus in poststroke epilepsy following acute ischemic stroke.Data on the effectiveness of third-generation ASMs in patients with status epilepticus in poststroke epilepsy were gathered from two German Stroke Registries and the Mainz Epilepsy Registry. We included only cases with epilepsy remote to the ischemic event. No patients with acute symptomatic seizures were included. The following third-generation ASMs were included: brivaracetam, lacosamide, eslicarbazepine, perampanel, topiramate, and zonisamide. The assessment of effectiveness was based on seizure freedom within 48 h since the start of therapy with the respective ASM. Seizure freedom was evaluated both clinically (clinical evaluation at least three times per day) and by daily electroencephalogram records.Of the 138 patients aged 70.8 ± 8.1 years with benzodiazepine-refractory status epilepticus in ischemic poststroke epilepsy, 33 (23.9%) were treated with lacosamide, 24 (17.4%) with brivaracetam, 23 (16.7%) with eslicarbazepine, 21 (15.2%) with perampanel, 20 (14.5%) with topiramate, and 17 (12.3%) with zonisamide. Seizure freedom within 48 h was achieved in 66.7% of patients with lacosamide, 65.2% with eslicarbazepine, 38.1% with perampanel, 37.5% with brivaracetam, 35.0% with topiramate, and 35.3% with zonisamide (p < 0.05 for comparison of lacosamide or eslicarbazepine to other ASMs).Based on these data, lacosamide and eslicarbazepine might be more favorable in the treatment of refractory status epilepticus in poststroke epilepsy, when administered as second- or third-line ASMs before anesthesia. Because of the fact that these ASMs share the same mechanism of action (slow inactivation of sodium channels), our findings could motivate further research on the role that this pharmaceutical mechanism of action has in the treatment of poststroke epilepsy.This study was registered at ClinicalTrials.gov (NCT05267405)." @default.
- W4387294016 created "2023-10-03" @default.
- W4387294016 creator A5011665420 @default.
- W4387294016 creator A5020519718 @default.
- W4387294016 creator A5033055839 @default.
- W4387294016 creator A5063142342 @default.
- W4387294016 creator A5072182050 @default.
- W4387294016 creator A5051896368 @default.
- W4387294016 date "2023-10-02" @default.
- W4387294016 modified "2023-10-13" @default.
- W4387294016 title "Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study" @default.
- W4387294016 cites W1526822959 @default.
- W4387294016 cites W1921203906 @default.
- W4387294016 cites W1939319747 @default.
- W4387294016 cites W1973232155 @default.
- W4387294016 cites W1978437325 @default.
- W4387294016 cites W1984152669 @default.
- W4387294016 cites W1995904934 @default.
- W4387294016 cites W2008984641 @default.
- W4387294016 cites W2011135728 @default.
- W4387294016 cites W2036215984 @default.
- W4387294016 cites W2037292769 @default.
- W4387294016 cites W2074583516 @default.
- W4387294016 cites W2074979385 @default.
- W4387294016 cites W2095071314 @default.
- W4387294016 cites W2101233529 @default.
- W4387294016 cites W2110531075 @default.
- W4387294016 cites W2142796780 @default.
- W4387294016 cites W2160763977 @default.
- W4387294016 cites W2161481721 @default.
- W4387294016 cites W2172052263 @default.
- W4387294016 cites W2400791935 @default.
- W4387294016 cites W2404739270 @default.
- W4387294016 cites W2551411640 @default.
- W4387294016 cites W2587813173 @default.
- W4387294016 cites W2770347852 @default.
- W4387294016 cites W2783592187 @default.
- W4387294016 cites W2791923869 @default.
- W4387294016 cites W2799465223 @default.
- W4387294016 cites W2914118809 @default.
- W4387294016 cites W2920667467 @default.
- W4387294016 cites W3008785252 @default.
- W4387294016 cites W3044784302 @default.
- W4387294016 cites W3129605045 @default.
- W4387294016 cites W3136658937 @default.
- W4387294016 cites W3143089179 @default.
- W4387294016 cites W3145030919 @default.
- W4387294016 cites W3180492948 @default.
- W4387294016 cites W3195824221 @default.
- W4387294016 cites W3198411327 @default.
- W4387294016 cites W4200292055 @default.
- W4387294016 cites W4200485500 @default.
- W4387294016 cites W4280581098 @default.
- W4387294016 cites W4284971359 @default.
- W4387294016 cites W4298087494 @default.
- W4387294016 cites W4319302860 @default.
- W4387294016 cites W4324091403 @default.
- W4387294016 doi "https://doi.org/10.1007/s40263-023-01039-y" @default.
- W4387294016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784006" @default.
- W4387294016 hasPublicationYear "2023" @default.
- W4387294016 type Work @default.
- W4387294016 citedByCount "0" @default.
- W4387294016 crossrefType "journal-article" @default.
- W4387294016 hasAuthorship W4387294016A5011665420 @default.
- W4387294016 hasAuthorship W4387294016A5020519718 @default.
- W4387294016 hasAuthorship W4387294016A5033055839 @default.
- W4387294016 hasAuthorship W4387294016A5051896368 @default.
- W4387294016 hasAuthorship W4387294016A5063142342 @default.
- W4387294016 hasAuthorship W4387294016A5072182050 @default.
- W4387294016 hasBestOaLocation W43872940161 @default.
- W4387294016 hasConcept C118552586 @default.
- W4387294016 hasConcept C127413603 @default.
- W4387294016 hasConcept C187212893 @default.
- W4387294016 hasConcept C2777138316 @default.
- W4387294016 hasConcept C2777341932 @default.
- W4387294016 hasConcept C2777683783 @default.
- W4387294016 hasConcept C2778139780 @default.
- W4387294016 hasConcept C2778186239 @default.
- W4387294016 hasConcept C2780645631 @default.
- W4387294016 hasConcept C2780836401 @default.
- W4387294016 hasConcept C42219234 @default.
- W4387294016 hasConcept C71924100 @default.
- W4387294016 hasConcept C78519656 @default.
- W4387294016 hasConceptScore W4387294016C118552586 @default.
- W4387294016 hasConceptScore W4387294016C127413603 @default.
- W4387294016 hasConceptScore W4387294016C187212893 @default.
- W4387294016 hasConceptScore W4387294016C2777138316 @default.
- W4387294016 hasConceptScore W4387294016C2777341932 @default.
- W4387294016 hasConceptScore W4387294016C2777683783 @default.
- W4387294016 hasConceptScore W4387294016C2778139780 @default.
- W4387294016 hasConceptScore W4387294016C2778186239 @default.
- W4387294016 hasConceptScore W4387294016C2780645631 @default.
- W4387294016 hasConceptScore W4387294016C2780836401 @default.
- W4387294016 hasConceptScore W4387294016C42219234 @default.
- W4387294016 hasConceptScore W4387294016C71924100 @default.
- W4387294016 hasConceptScore W4387294016C78519656 @default.
- W4387294016 hasFunder F4320325874 @default.
- W4387294016 hasFunder F4320336167 @default.
- W4387294016 hasLocation W43872940161 @default.
- W4387294016 hasLocation W43872940162 @default.